Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,498 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study.
Serruys PW, Garg S, Abizaid A, Ormiston J, Windecker S, Verheye S, Dubois C, Stewart J, Hauptmann KE, Schofer J, Stangl K, Witzenbichler B, Wiemer M, Barbato E, de Vries T, den Drijver AM, Otake H, Meredith L, Toyloy S, Fitzgerald P. Serruys PW, et al. Among authors: windecker s. EuroIntervention. 2010 Jun;6(2):195-205. EuroIntervention. 2010. PMID: 20562069 Clinical Trial.
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, García-García HM. Serruys PW, et al. Among authors: windecker s. Circulation. 2010 Nov 30;122(22):2301-12. doi: 10.1161/CIRCULATIONAHA.110.970772. Epub 2010 Nov 15. Circulation. 2010. PMID: 21098436
Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study.
Brugaletta S, Garcia-Garcia HM, Diletti R, Gomez-Lara J, Garg S, Onuma Y, Shin ES, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn R, Dorange C, Veldhof S, Rapoza R, Sudhir K, Bruining N, Ormiston JA, Serruys PW. Brugaletta S, et al. Among authors: windecker s. EuroIntervention. 2011 Apr;6(9):1110-6. doi: 10.4244/EIJV6I9A193. EuroIntervention. 2011. PMID: 21518685 Clinical Trial.
6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm.
Diletti R, Onuma Y, Farooq V, Gomez-Lara J, Brugaletta S, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn R, Smits P, Koolen J, Meredith I, Li D, Veldhof S, Rapoza R, Garcia-Garcia HM, Ormiston JA, Serruys PW. Diletti R, et al. Among authors: windecker s. J Am Coll Cardiol. 2011 Jul 12;58(3):258-64. doi: 10.1016/j.jacc.2011.02.052. J Am Coll Cardiol. 2011. PMID: 21737016 Free article.
Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation.
Wenaweser P, Pilgrim T, Guerios E, Stortecky S, Huber C, Khattab AA, Kadner A, Buellesfeld L, Gloekler S, Meier B, Carrel T, Windecker S. Wenaweser P, et al. Among authors: windecker s. EuroIntervention. 2011 Sep;7(5):541-8. doi: 10.4244/EIJV7I5A89. EuroIntervention. 2011. PMID: 21930453 Free article.
Comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction (COMFORTABLE AMI trial): rationale and design.
Räber L, Kelbaek H, Ostoijc M, Baumbach A, Tüller D, von Birgelen C, Roffi M, Pedrazzini G, Kornowski R, Weber K, Heg D, Matter C, Lüscher T, Taniwaki M, Meier B, Jüni P, Windecker S. Räber L, et al. Among authors: windecker s. EuroIntervention. 2012 Apr;7(12):1435-43. doi: 10.4244/EIJV7I12A224. EuroIntervention. 2012. PMID: 22301368 Free article. Clinical Trial.
First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Garcia-Garcia HM. Ormiston JA, et al. Among authors: windecker s. Circ Cardiovasc Interv. 2012 Oct;5(5):620-32. doi: 10.1161/CIRCINTERVENTIONS.112.971549. Epub 2012 Oct 9. Circ Cardiovasc Interv. 2012. PMID: 23048057 Clinical Trial.
Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.
Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Ormiston JA. Serruys PW, et al. Among authors: windecker s. EuroIntervention. 2014 Mar 20;9(11):1271-84. doi: 10.4244/EIJV9I11A217. EuroIntervention. 2014. PMID: 24291783 Free article. Clinical Trial.
1,498 results